Skip to content
Home/Companies/Biotech/HI-Bio

HI-Bio

Biotech·France·Exited 2024·Held 3yr
Entry
2021
Hold
3yr
Exit
2024

Who owns HI-Bio?

HI-Bio is a French Biotech company, now owned by Biogen, which acquired it in 2024 from Jeito Capital.

Hand-verified · updated 2026-09-30

Open JSON · CC-BY
Jeito Capital
Investor
Jeito Capital
Jeito I · 2021 · VC

Key facts

HQFrance
SectorBiotech
Exit Type
Trade Sale
Buyer
Biogen
Exit Year
2024

More from Jeito I

Other portfolio companies in the same fund.

Corteria Pharmaceuticals
Corteria Pharmaceuticals
Active
BiotechFrance· 2023
Noema Pharma
Noema Pharma
Active
BiotechSwitzerland· 2023
Advesya
Advesya
Active
BiotechSpain· 2022
CatalYm
CatalYm
Active
BiotechGermany· 2022
CDR-Life
CDR-Life
Active
BiotechSwitzerland· 2022
EyeBio
Exited 2024
BiotechUS· 2022
to Merck

More PE-backed in Biotech

Comparable biotech deals from other GPs.

Abbisko Healthcare
Active
The Carlyle GroupChina
Adagene
Active
General AtlanticChina
Advanced Cell Diagnostics
Active
Summit PartnersUS
Akero Therapeutics
Akero Therapeutics
Active
General AtlanticUS
Aldevron
Aldevron
Active
TA AssociatesUS
Alloy Therapeutics
Alloy Therapeutics
Active
Mubadala CapitalUS

Questions

Who owns HI-Bio?

HI-Bio is now owned by Biogen, which acquired it in 2024 from Jeito Capital.

When did Biogen acquire HI-Bio?

Biogen acquired HI-Bio in 2024, buying from Jeito Capital.

Who did HI-Bio sell to?

Jeito Capital sold HI-Bio to Biogen in 2024 (Trade Sale).

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue